Adherence of Community Pharmacies in Riyadh, Saudi Arabia, to Optimal Conditions for Keeping and Selling Good-Quality Medicines


Exposure to excessive temperature during distribution or storage has unfavorable consequences on the quality of medicines, particularly in hot climates. This could be one of the possible reasons behind the existence of substandard amoxicillin in community pharmacies in Riyadh, Saudi Arabia. This study explored the conditions under which medicines were kept in a random sample of 181 community pharmacies in Riyadh. The pharmacist in charge in each pharmacy was interviewed and our observations about the quality of storage were recorded. The inspection revealed that in 9% of the sample the readings of the existing room thermometers were >25℃, and that 13% of the sample lacked thermometers. Also in 33% of the sample the readings of the refrigerator thermometers were outside the accepted range, and 7% of the sample lacked refrigerator thermometers. About 15% of pharmacists were not informed about the local regulations of community pharmacy practice, neither before nor after taking up their current positions. Surprisingly, incorrect answers to simple questions about the system were frequently given by the informed pharmacists. Certain aspects of substandard storage conditions existed, in varying degrees, in significant percentages of pharmacies regardless of the pharmacists’ qualifications, experience, or awareness about the local regulations of community pharmacy practice. Stricter monitoring by the authorities regarding the adherence of community pharmacies to optimal conditions of storing medicines is recommended. Continuing education of community pharmacists must also be improved.

Share and Cite:

H. Khojah, H. Pallos, H. Tsuboi, N. Yoshida, H. Abou-Auda and K. Kimura, "Adherence of Community Pharmacies in Riyadh, Saudi Arabia, to Optimal Conditions for Keeping and Selling Good-Quality Medicines," Pharmacology & Pharmacy, Vol. 4 No. 5, 2013, pp. 431-437. doi: 10.4236/pp.2013.45061.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. Dégardina, Y. Roggoaand and P. Margot, “Understanding and Fighting the Medicine Counterfeit Market,” In Press for Journal of Pharmaceutical and Biomedical Analysis, 2013. doi:10.1016/j.jpba.2013.01.009
[2] T. K. Mackey and B. A. liang, “The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks,” Journal of Pharmaceutical Sciences, Vol. 100, No. 11, 2011, pp. 4571-4579. doi:10.1002/jps.22679
[3] J. M. Caudron, N. Ford, M. Henkens, C. Macé, R. Kiddle-Monroeand and J. Pine, “Substandard Medicines in Resource-Poor Settings: A Problem That Can No Longer be Ignored,” Tropical Medicine and International Health, Vol. 13, No. 8, 2008, pp. 1062-1072. doi:10.1111/j.1365-3156.2008.02106.x
[4] O. Shakoor, R. B. Taylor and R. H. Behrens, “Assessment of the Incidence of Substandard Drugs in Developing Countries,” Tropical Medicine and International Health, Vol. 2, No. 9, 1997, pp. 839-845. doi:10.1046/j.1365-3156.1997.d01-403.x
[5] F. M. Fernandez, D. Hostetler, K. Powell, H. Kaur, M. D. Green, D. C. Mildenhall and P. N. Newton, “Poor Quality Drugs: Grand Challenges in High Throughput Detection, Countrywide Sampling, and Forensics in Developing Countries,” Analyst, Vol. 136, No. 15, 2011, pp. 3073-3082. doi:10.1039/c0an00627k
[6] P. N. Newton, A. A. Amin, C. Bird, P. Passmore, G. Dukes, G. Tomson, B. Simons, R. Bate, P. J. Guerin and N. J. White, “The Primacy of Public Health Considerations in Defining Poor Quality Medicines,” PLoS Medicine, Vol. 8, No. 12, 2011, Article No: e1001139. doi:10.1371/journal.pmed.1001139
[7] H. M. J. Khojah, H. Pallos, N. Yoshida, M. Akazawa, H. Tsuboi and K. Kimura, “The Quality of Medicines in Community Pharmacies in Riyadh, Saudi Arabia: A Lot Quality Assurance Sampling (LQAS)-Based Survey,” unpublished, under reviewing.
[8] B. Crichton, “Keep in a Cool Place: Exposure of Medicines to High Temperatures in General Practice during a British Heat wave,” Journal of the Royal Society of Medicine, Vol. 97, No. 7, 2004, pp. 328-329. doi:10.1258/jrsm.97.7.328
[9] K. K. Naidoo, P. Nompuku, S. N. Mkalali, K. Shabangu, L. Nkabinde and V. Singh, “Post-Marketing Stability Surveillance: Amoxicillin,” South African Family Practice, Vol. 48, No. 6, 2006, p. 14.
[10] R. Ziance, C. Chandler and R. H. Bishara, “Integration of Temperature-Controlled Requirements into Pharmacy Practice,” Journal of the American Pharmacists Association, Vol. 49, No. 3, 2003, pp. 61-67. doi:10.1331/JAPhA.2009.08140
[11] Saudi Food and Drug Authority (SFDA), “Operational Regulations of the System for Private Pharmaceutical Facilities and Products,” in Arabic, accessed 2013 May 10.
[12] A. A. B. Abdulhak, M. A. Altannir, M. A. Almansor, M. S. Almohaya, A. S. Onazi, M. A. Marei, O. F. Aldossary, S. A. Obeidat, M. A. Obeidat, M. S. Riaz and I. M. Tleyjeh, “Non Prescribed Sale of Antibiotics in Riyadh, Saudi Arabia: A Cross Sectional Study,” BMC Public Health, Vol. 11, 2011, p. 538. doi:10.1186/1471-2458-11-538
[13] T. A. O. Najjar, “A Survey on Community Pharmacies in Riyadh, Saudi Arabia,” Saudi Pharmaceutical Journal, Vol. 9, No. 2, 2001, pp. 113-118.
[14] Z. A. Butt, A. H. Gilani, D. Nanan, A. L. Sheikh and F. White, “Quality of Pharmacies in Pakistan: A Cross-Sectional Survey,” International Journal for Quality in Health Care, Vol. 17, No. 4, 2005, pp. 307-313. doi:10.1093/intqhc/mzi049
[15] L. Syhakhang, B. Stenson, R. Wahlstrom and G. Tomson, “The Quality of Public and Private Pharmacy Practices,” European Journal of Clinical Pharmacology, Vol. 57, No. 3, 2001, pp. 221-227. doi:10.1007/s002280100295
[16] World Health Organization, “WHO Expert Committee on Specifications for Pharmaceutical Preparations,” Thirty-Seventh Report, World Health Organization, 2004, pp. 125-136, Accessed 2013 May 10.
[17] World Health Organization, “WHO Expert Committee on Specifications for Pharmaceutical Preparations,” Fortieth Report, World Health Organization, 2006, pp. 179-202. Accessed 2013 May 10.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.